Highlights from the ‘Noncoding RNA world: From Mechanism to Therapy’ conference, July 21-23, 2021

Abstract

Non-coding RNAs (ncRNAs) are involved in different cellular processes and some of them are considered to play a role in the development of numerous diseases. The recent discovery of ncRNAs is the result of several experimental and bioinformatics studies. On July 21-23, 2021, the 'Noncoding RNA World: From Mechanism to Therapy' conference that was held virtually (originally planned to be held in Basel, Switzerland), gathered experts and researchers from countries worldwide to cover the latest achievements in ncRNA research, including the basic molecular mechanisms and structural biology, bioinformatics, biotechnology, disease development and therapeutics of ncRNAs. The meeting was dominated by a feeling of satisfaction and enthusiasm for the novel discoveries in the ncRNA field that is considered to be relatively new. Intriguingly, several discoveries are added daily beside numerous hurdles that are encountered or remain to be resolved in order for these findings to be translated into clinical practice.

Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review)

“…Il-17a contributes to neuroinflammation in disorders, including Parkinson's disease (PD), alzheimer's disease (aD) and amyotrophic lateral sclerosis. Patients with MS, aD and PD have considerably higher levels of Il-17a in their CSF and plasma, and Il-17a expression levels are associated with the severity and progression of the disorders (74,(76)(77)(78)(79)(80). IL-17A increases inflammation and it functions more as a regulatory element in the network of generated cytokines than as a direct mediator of tissue injury (81)(82)(83).…”